TY - JOUR
T1 - Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis
AU - Gaudet, Mia M.
AU - Hunter, Kent
AU - Pharoah, Paul
AU - Dunning, Alison M.
AU - Driver, Kristy
AU - Lissowska, Jolanta
AU - Sherman, Mark
AU - Peplonska, Beata
AU - Brinton, Louise A.
AU - Chanock, Stephen
AU - Garcia-Closas, Montserrat
PY - 2009/4/1
Y1 - 2009/4/1
N2 - Genetic variation in SIPA1, signal-induced proliferation-associated gene 1, has been proposed to be associated with aggressive breast tumor characteristics related to metastasis and worse prognosis in humans and rodents. To test this hypothesis, we genotyped 3 single nucleotide polymorphisms (SNP) located at -3092 (AT, rs3741378), and exon 14 1 14 (C>T, rs746429), and examined them in relation to breast cancer risk and overall survival, stratified by tumor characteristics in 2 independent case-control studies conducted in Poland (1,995 cases, 2,296 controls) and in Britain (2,142 cases, 2,257 controls). Vital status (n = 396 deaths) was available for 911 Polish and 1,919 British breast cancer cases with an average follow-up time of 5.5 years. Overall, we found no significant associations between genetic variants of SIPA1 SNPs and breast cancer risk (per allele odds ratios, 95% confidence intervals (CI): rs931127-0.99, 0.931.06; rs3741378-1.03, 0.94-1.13; and, rs74642-0.98, 0.92-1.04). In both studies, SIPA1 polymorphisms were not related to overall mortality (per allele hazard ratios, 95% CI: 1.02, 0.88-1.17; 0.90, 0.72-1.11; 1.04, 0.90-1.21, respectively). Our results do not support a relationship between SIPA1 polymorphisms and breast cancer risk or subsequent survival.
AB - Genetic variation in SIPA1, signal-induced proliferation-associated gene 1, has been proposed to be associated with aggressive breast tumor characteristics related to metastasis and worse prognosis in humans and rodents. To test this hypothesis, we genotyped 3 single nucleotide polymorphisms (SNP) located at -3092 (AT, rs3741378), and exon 14 1 14 (C>T, rs746429), and examined them in relation to breast cancer risk and overall survival, stratified by tumor characteristics in 2 independent case-control studies conducted in Poland (1,995 cases, 2,296 controls) and in Britain (2,142 cases, 2,257 controls). Vital status (n = 396 deaths) was available for 911 Polish and 1,919 British breast cancer cases with an average follow-up time of 5.5 years. Overall, we found no significant associations between genetic variants of SIPA1 SNPs and breast cancer risk (per allele odds ratios, 95% confidence intervals (CI): rs931127-0.99, 0.931.06; rs3741378-1.03, 0.94-1.13; and, rs74642-0.98, 0.92-1.04). In both studies, SIPA1 polymorphisms were not related to overall mortality (per allele hazard ratios, 95% CI: 1.02, 0.88-1.17; 0.90, 0.72-1.11; 1.04, 0.90-1.21, respectively). Our results do not support a relationship between SIPA1 polymorphisms and breast cancer risk or subsequent survival.
UR - http://www.scopus.com/inward/record.url?scp=61449175948&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=61449175948&partnerID=8YFLogxK
U2 - 10.1002/ijc.23919
DO - 10.1002/ijc.23919
M3 - Article
C2 - 19089925
AN - SCOPUS:61449175948
SN - 0020-7136
VL - 124
SP - 1716
EP - 1720
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 7
ER -